ClinicalTrials.gg
CompletedNCT00390910Updated Dec 17, 2018Results posted

Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants

A Phase 3 interventional study of Pneumococcal conjugate vaccine GSK1024850A and Infanrix hexa in Infections, Streptococcal, sponsored by GlaxoSmithKline. Completed at 8 sites in 2 countries. Open to participants aged 8 Weeks to 16 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-17.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Non-randomized
Ages
8 Weeks to 16 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 64 studies in Streptococcal Infections by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Streptococcal Infections · GlaxoSmithKline.

Enrollment
36th of 55
286 · median 365
Started
2006
with 8 others
Phase 3
38 of 64
none open now
Registered
12th of 64
by date

Among the 64 studies in Streptococcal Infections by GlaxoSmithKline, this one is the 36th largest by enrollment of the 55 interventional ones that give a count, is one of 9 that started in 2006, is one of 38 in phase 3, and was the 12th registered.

Streptococcal Infections

147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.

Browse Streptococcal Infections studies →

Open to participants now

1 of the 64 studies in Streptococcal Infections by GlaxoSmithKline is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 8 Weeks to 16 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Streptococcal Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis B virus-inactivated polio virus/Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) vaccine in preterm infants as a 3-dose primary immunization course during the first 6 months of life.

This protocol posting deals with objectives \& outcome measures of the primary study. The objectives \& outcome measures of the Booster study are presented in a separate protocol posting (NCT number = 00609492)

Read the detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

03

Conditions studied

  • Infections, Streptococcal

Keywords

  • Pneumococcal vaccine
  • Preterm
  • Safety
  • Pneumococcal disease
  • Immunogenicity
04

Who can participate

Ages eligible
8 Weeks to 16 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol
  • A male or female between, and including, 8-16 weeks (56-118 days) of age at the time of the first vaccination.
  • Written obtained from the parent or guardian of the subject.
  • Born after a gestation period of >27 weeks (at least 189 days).
  • If full term born, healthy subjects as established by medical history and clinical examination before entering into the study
  • If premature, medically stable condition (not requiring significant medical support or ongoing management for debilitating disease and having demonstrated a clinical course of sustained recovery).

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs from birth to the first vaccine dose.
  • Planned administration/administration of a vaccine not foreseen by the study protocol, during the period starting from one month before the first dose of vaccines and up to Visit 6.
  • Previous vaccination against diphtheria, tetanus, pertussis, polio, , Haemophilus influenzae type b, Neisseria meningitidis and/or Streptococcus pneumoniae with the exception of vaccines where the first dose can be given within the first two weeks of life according to the national recommendations
  • History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b disease, Neisseria meningitidis.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • History of any neurologic disorders or seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past).
  • Acute disease at the time of enrolment.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
  • A family history of congenital or hereditary immunodeficiency.
  • Major congenital defects or serious chronic illness.
  • Administration of immunoglobulins, with the exception of monoclonal antibodies against RSV, and/or any blood products within one month preceding the first dose of study vaccines or planned administration during the active phase of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    Synflorix™ + Infanrix™ hexa Group I

    Very preterm infants born after a gestation period of 27-30 weeks (189-216 days)

    Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa

  • Experimental
    Synflorix™ + Infanrix™ hexa Group II

    Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)

    Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa

  • Experimental
    Synflorix™ + Infanrix™ hexa Group III

    Infants born after a gestation period of more than 36 weeks (more than 258 days)

    Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Core Fever (Rectal Temperature) Greater Than (>) the Cut-off

    Fever was measured as rectal temperature. Assessment of occurrences of fever \> 39.0 °C was performed post doses 1, 2 and 3 of Synflorix or Infanrix hexa vaccine.

    Time frame: Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)

Secondary outcomes

  1. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Solicited local symptoms assessed included pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\>) 30 millimeters (mm). "Any" was defined as incidence of the specified symptom regardless of intensity.

    Time frame: Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)

  2. Number of Subjects With Any and Grade 3 Solicited General Symptoms

    Solicited general symptoms assessed included drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. "Any" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.

    Time frame: Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)

  3. Number of Subjects With Any Unsolicited Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.

    Time frame: Within 31 days (Days 0-30) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)

  4. Number of Subjects With Any Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.

    Time frame: Throughout the active phase of the study (from the first vaccine administration (Month 0) up to 1 month after the third vaccine administration (Month5).

  5. Number of Subjects With Any Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.

    Time frame: Throughout the entire study period starting from the first vaccine dose administration (Month 0) up to the end of the 6-month safety follow-up (ESFU- Month 10).

  6. Number of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Greater Than or Equal to (≥) the Cut-off

    The cut-off for the assay was ≥ 0.20 microgram per mililiter (μg/ mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  7. Number of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off

    The cut-off for the assay was ≥ 0.05 microgram per mililiter (μg/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  8. Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F

    Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  9. Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off

    The cut-off for the assay was ≥ 8

    Time frame: One month after the 3rd vaccine dose (Month 5)

  10. Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F

    Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.

    Time frame: One month after the 3rd vaccine dose (Month 5)

  11. Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off

    The cut-off for the assay was ≥ 0.05 microgram per milliliter (μg/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  12. Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A

    Seropositivity status was defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  13. Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off

    The cut-off for the assay was ≥ 8.

    Time frame: One month after the 3rd vaccine dose (Month 5)

  14. Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A

    Seropositivity status was defined as opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.

    Time frame: One month after the 3rd vaccine dose (Month 5)

  15. Number of Subjects With Concentrations of Antibodies Against Protein D (Anti-PD) ≥ the Cut-off

    The cut-off for the assay was ≥ 100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  16. Concentrations of Antibodies Against Protein D (Anti-PD)

    Seropositivity status was defined as anti-PD antibody concentrations ≥ 100 ELISA units per milliliter ( EL.U/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  17. Number of Subjects With Anti-diphtheria (Anti DT) and Anti-tetanus Toxoids (Anti TT) Antibody Concentrations ≥ the Cut-off

    The cut-off for the assay was ≥ 0.1 international units per milliliter (IU/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  18. Antibody Concentrations for Anti-diphtheria and Tetanus Toxoids ≥ the Cut-off

    Seroprotection status was defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 IU/mL

    Time frame: One month after the 3rd vaccine dose (Month 5)

  19. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off

    The cut-off for the assay was ≥ 0.15 microgram per milliliter (μg/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  20. Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off

    The cut-off for the assay was ≥ 1.0 microgram per milliliter (μg/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  21. Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations ≥ th Cut-off

    Seroprotection status was defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL

    Time frame: One month after the 3rd vaccine dose (Month 5)

  22. Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations ≥ the Cut-off

    The cut-off for the assay was ≥ 5 ELISA unit per milliliter (EL.U/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  23. Antibody Concentration for Anti-pertussis Toxoid (Anti-PT) , Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)

    Seropositivity status was defined as anti-PT, anti-FHA, anti-PRN antibody concentrations ≥ 5 EL.U/mL.

    Time frame: One month after the 3rd vaccine dose (Month 5)

  24. Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off.

    The cut-off for the assay was ≥ 10 milli-international units per milliliter (mIU/mL).

    Time frame: One month after the 3rd vaccine dose (Month 5)

  25. Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations

    Seroprotection status was defined as Anti-HBs antibody concentrations ≥ 10 mIU/mL

    Time frame: One month after the 3rd vaccine dose (Month 5)

  26. Number of Subjects With Anti-polio Type 1, 2 and 3 Antibody Titres

    The cut-off for the assay was ≥ 8.

    Time frame: One month after the 3rd vaccine dose (Month 5)

  27. Antibody Titers for Polio Type 1, 2 and 3 ≥ the Cut-off

    Seroprotection status was defined as Anti-polio type 1, Anti-polio type 2 and Anti-polio type 3 antibody titers ≥ 8.

    Time frame: One month after the 3rd vaccine dose (Month 5)

  28. Number of Subjects With Vaccine Response to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)

    Vaccine response to PT, FHA and PRN was defined as appearance of antibodies in subjects who are initially seronegative (S-), or at least maintenance of pre-vaccination antibody concentrations in those who are initially seropositive (S+). For the SYNFLORIX™ + INFANRIX™ HEXA GROUP I, no subjects presented initial seropositivity for PT and PRN antigens.

    Time frame: One month after the 3rd vaccine dose (Month 5)

07

Results

Posted Dec 17, 2018

Participant flow

For each subject the study duration was approximately 5 months for the active phase (Month 0 untill one month after last vaccination) and 10 months, including the 5 months extended safety follow-up.

Participant flow — Overall Study
MilestoneSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Started5087149
Completed4883139
Not completed2410
Withdrew: Adverse event100
Withdrew: Lost to follow-up015
Withdrew: Withdrawal by subject132
Withdrew: Migrated/moved from study area003

Outcome measures

PrimaryNumber of Subjects With Core Fever (Rectal Temperature) Greater Than (>) the Cut-off

Fever was measured as rectal temperature. Assessment of occurrences of fever \> 39.0 °C was performed post doses 1, 2 and 3 of Synflorix or Infanrix hexa vaccine.

Time frame:
Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)
Reported as:
Count of participants · Participants
Number of Subjects With Core Fever (Rectal Temperature) Greater Than (>) the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group IIIPooled Group I + II
Fever > 39.0°C, post Dose 152
Fever > 39.0°C, post Dose 211
Fever > 39.0°C, post Dose 331
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Solicited local symptoms assessed included pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\>) 30 millimeters (mm). "Any" was defined as incidence of the specified symptom regardless of intensity.

Time frame:
Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsSynflorix™ + Infanrix™ Hexa Group IIIPooled Group I + II
Any pain, Post Dose 15840
Grade 3 pain, Post Dose 166
Any redness, Post Dose 16739
Grade 3 redness, Post Dose 101
Any swelling, Post Dose 16730
Grade 3 swelling, Post Dose 121
Any pain, Post Dose 23939
Grade 3 pain, Post Dose 219
Any redness, Post Dose 27241
Grade 3 redness, Post Dose 270
Any swelling, Post Dose 26030
Grade 3 swelling, Post Dose 240
Any pain, Post Dose 34230
Grade 3 pain, Post Dose 363
Any redness, Post Dose 36633
Grade 3 redness, Post Dose 393
Any swelling, Post Dose 35824
Grade 3 swelling, Post Dose 362
SecondaryNumber of Subjects With Any and Grade 3 Solicited General Symptoms

Solicited general symptoms assessed included drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. "Any" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.

Time frame:
Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited General Symptoms
ParticipantsSynflorix™ + Infanrix™ Hexa Group IIIPooled Group I + II
Any drowsiness, Post Dose 15344
Grade 3 drowsiness, Post Dose 121
Any fever(rectally), Post Dose 13841
Grade 3 fever(rectally), Post Dose 110
Any irritability, Post Dose 17353
Grade 3 irritability, Post Dose 196
Any loss of appetite, Post Dose 13633
Grade 3 loss of appetite, Post Dose 100
Any drowsiness, Post Dose 23432
Grade 3 drowsiness, Post Dose 201
Any fever(rectally), Post Dose 23440
Grade 3 fever(rectally), Post Dose 200
Any irritability, Post Dose 25351
Grade 3 irritability, Post Dose 224
Any loss of appetite, Post Dose 22335
Grade 3 loss of appetite, Post Dose 202
Any drowsiness, Post Dose 32218
Grade 3 drowsiness, Post Dose 314
Any fever(rectally), Post Dose 32516
Grade 3 fever(rectally), Post Dose 310
Any irritability, Post Dose 34440
Grade 3 irritability, Post Dose 313
Any loss of appetite, Post Dose 32226
Grade 3 loss of appetite, Post Dose 301
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.

Time frame:
Within 31 days (Days 0-30) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs)
ParticipantsSynflorix™ + Infanrix™ Hexa Group IIIPooled Group I + II
Number of Subjects With Any Unsolicited Adverse Events (AEs)5843
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.

Time frame:
Throughout the active phase of the study (from the first vaccine administration (Month 0) up to 1 month after the third vaccine administration (Month5).
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs)
ParticipantsSynflorix™ + Infanrix™ Hexa Group IIIPooled Group I + II
Number of Subjects With Any Serious Adverse Events (SAEs)1318
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.

Time frame:
Throughout the entire study period starting from the first vaccine dose administration (Month 0) up to the end of the 6-month safety follow-up (ESFU- Month 10).
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs)
ParticipantsSynflorix™ + Infanrix™ Hexa Group IIIPooled Group I + II
Number of Subjects With Any Serious Adverse Events (SAEs)1929
SecondaryNumber of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Greater Than or Equal to (≥) the Cut-off

The cut-off for the assay was ≥ 0.20 microgram per mililiter (μg/ mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Greater Than or Equal to (≥) the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-14182129
Anti-44081130
Anti-54282129
Anti-6B3878123
Anti-7F4182131
Anti-9V4082132
Anti-144182132
Anti-18C4181130
Anti-19F4282132
Anti-23F3979125
SecondaryNumber of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off

The cut-off for the assay was ≥ 0.05 microgram per mililiter (μg/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-14282130
Anti-44182130
Anti-54282129
Anti-6B4081131
Anti-7F4182131
Anti-9V4182132
Anti-144182132
Anti-18C4181131
Anti-19F4282132
Anti-23F3981129
SecondaryConcentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F

Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · μg/mL
Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
μg/mLSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-10.97 (0.75 to 1.26)1.1 (0.93 to 1.3)1.35 (1.18 to 1.55)
Anti-41.53 (1.19 to 1.98)1.88 (1.61 to 2.2)2.42 (2.13 to 2.74)
Anti-51.45 (1.13 to 1.86)1.93 (1.65 to 2.25)2.31 (2 to 2.66)
Anti-6B0.85 (0.61 to 1.19)1.11 (0.89 to 1.37)1.18 (1 to 1.39)
Anti-7F1.87 (1.47 to 2.39)2.37 (2.07 to 2.73)2.69 (2.39 to 3.03)
Anti-9V1.43 (1.17 to 1.74)1.69 (1.44 to 1.99)2.41 (2.13 to 2.73)
Anti-143.52 (2.81 to 4.42)3.28 (2.77 to 3.89)3.71 (3.21 to 4.3)
Anti-18C3.28 (2.51 to 4.29)4.86 (3.92 to 6.02)5.22 (4.27 to 6.38)
Anti-19F3.6 (2.83 to 4.57)4.8 (4.15 to 5.55)4.56 (3.95 to 5.26)
Anti-23F1.05 (0.74 to 1.49)1.33 (1.07 to 1.65)1.54 (1.28 to 1.85)
SecondaryNumber of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off

The cut-off for the assay was ≥ 8

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Opsono-1204980
Opsono-43672110
Opsono-52969104
Opsono-6B305985
Opsono-7F3674113
Opsono-9V3672103
Opsono-143673110
Opsono-18C346599
Opsono-19F3171105
Opsono-23F3570109
SecondaryOpsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F

Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
TitersSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Opsono-123 (13 to 40.6)30.3 (20.5 to 44.8)46.3 (33.4 to 64.1)
Opsono-4644.1 (474.6 to 874)500.9 (384.5 to 652.5)543.5 (450.6 to 655.5)
Opsono-545.2 (27.7 to 73.8)70.8 (52.3 to 95.7)94.8 (75.7 to 118.7)
Opsono-6B278.3 (125.5 to 617.3)305.1 (180.1 to 516.9)268.2 (167.5 to 429.4)
Opsono-7F4086.3 (2834.3 to 5891.3)3047.3 (2422.2 to 3833.7)2395.2 (1973.2 to 2907.5)
Opsono-9V930.5 (603.1 to 1435.6)837.9 (642.7 to 1092.3)1144.8 (922.3 to 1421)
Opsono-14775.4 (539 to 1115.5)901.6 (699.8 to 1161.6)644.6 (514.9 to 807)
Opsono-18C262.5 (159.4 to 432.4)321.5 (220.9 to 467.7)251 (189 to 333.4)
Opsono-19F104.2 (61.5 to 176.5)201.1 (149.7 to 270.1)182.7 (139.2 to 239.7)
Opsono-23F1659.4 (975.1 to 2824)1147.2 (843 to 1561.2)1558.8 (1302.6 to 1865.3)
SecondaryNumber of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off

The cut-off for the assay was ≥ 0.05 microgram per milliliter (μg/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-6A3268114
Anti-19A2672120
SecondaryConcentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A

Seropositivity status was defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · μg/mL
Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A
μg/mLSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-6A0.14 (0.09 to 0.2)0.21 (0.15 to 0.28)0.2 (0.16 to 0.25)
Anti-19A0.08 (0.06 to 0.11)0.21 (0.16 to 0.28)0.26 (0.21 to 0.32)
SecondaryNumber of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off

The cut-off for the assay was ≥ 8.

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Opsono-6A255458
Opsono-19A21017
SecondaryOpsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A

Seropositivity status was defined as opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A
TitersSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Opsono-6A114.5 (52.8 to 248.5)157.3 (95.8 to 258.4)49.5 (31.8 to 76.9)
Opsono-19A4.5 (3.8 to 5.4)7.1 (4.9 to 10.1)7 (5.4 to 9.2)
SecondaryNumber of Subjects With Concentrations of Antibodies Against Protein D (Anti-PD) ≥ the Cut-off

The cut-off for the assay was ≥ 100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Concentrations of Antibodies Against Protein D (Anti-PD) ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Number of Subjects With Concentrations of Antibodies Against Protein D (Anti-PD) ≥ the Cut-off4282130
SecondaryConcentrations of Antibodies Against Protein D (Anti-PD)

Seropositivity status was defined as anti-PD antibody concentrations ≥ 100 ELISA units per milliliter ( EL.U/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · EL.U/mL
Concentrations of Antibodies Against Protein D (Anti-PD)
EL.U/mLSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Concentrations of Antibodies Against Protein D (Anti-PD)1688.6 (1320.1 to 2159.8)1415.4 (1167.1 to 1716.5)1496.8 (1283.4 to 1745.8)
SecondaryNumber of Subjects With Anti-diphtheria (Anti DT) and Anti-tetanus Toxoids (Anti TT) Antibody Concentrations ≥ the Cut-off

The cut-off for the assay was ≥ 0.1 international units per milliliter (IU/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-diphtheria (Anti DT) and Anti-tetanus Toxoids (Anti TT) Antibody Concentrations ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-diphtheria184161
Anti-tetanus184161
SecondaryAntibody Concentrations for Anti-diphtheria and Tetanus Toxoids ≥ the Cut-off

Seroprotection status was defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 IU/mL

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · IU/mL
Antibody Concentrations for Anti-diphtheria and Tetanus Toxoids ≥ the Cut-off
IU/mLSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-diphtheria2.495 (1.664 to 3.741)3.23 (2.628 to 3.969)3.077 (2.481 to 3.817)
Anti-tetanus7.745 (6.284 to 9.545)8.617 (7.216 to 10.29)7.695 (6.838 to 8.66)
SecondaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off

The cut-off for the assay was ≥ 0.15 microgram per milliliter (μg/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off184163
SecondaryNumber of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off

The cut-off for the assay was ≥ 1.0 microgram per milliliter (μg/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off163860
SecondaryAnti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations ≥ th Cut-off

Seroprotection status was defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · μg/mL
Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations ≥ th Cut-off
μg/mLSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations ≥ th Cut-off4.031 (2.261 to 7.184)5.804 (4.12 to 8.178)7.952 (5.839 to 10.831)
SecondaryNumber of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations ≥ the Cut-off

The cut-off for the assay was ≥ 5 ELISA unit per milliliter (EL.U/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations ≥ the Cut-off
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-PT184161
Anti-FHA184161
Anti-PRN174060
SecondaryAntibody Concentration for Anti-pertussis Toxoid (Anti-PT) , Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)

Seropositivity status was defined as anti-PT, anti-FHA, anti-PRN antibody concentrations ≥ 5 EL.U/mL.

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · EL.U/mL
Antibody Concentration for Anti-pertussis Toxoid (Anti-PT) , Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)
EL.U/mLSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-PT41.9 (27.6 to 63.7)37.9 (30.7 to 46.7)47.3 (40.2 to 55.7)
Anti-FHA188.6 (133.4 to 266.6)169 (139.6 to 204.7)163.1 (138.3 to 192.3)
Anti-PRN127.6 (81.5 to 199.6)109.1 (85.7 to 139)119.1 (101.1 to 140.4)
SecondaryNumber of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off.

The cut-off for the assay was ≥ 10 milli-international units per milliliter (mIU/mL).

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off.
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off.82612
SecondaryAnti-hepatitis B Surface Antigen (HBs) Antibody Concentrations

Seroprotection status was defined as Anti-HBs antibody concentrations ≥ 10 mIU/mL

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · mIU/mL
Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations
mIU/mLSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations431.9 (240.7 to 775.2)356 (221.1 to 573.4)462.9 (221.1 to 969.1)
SecondaryNumber of Subjects With Anti-polio Type 1, 2 and 3 Antibody Titres

The cut-off for the assay was ≥ 8.

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-polio Type 1, 2 and 3 Antibody Titres
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-Polio 1122229
Anti-Polio 2122229
Anti-Polio 3102129
SecondaryAntibody Titers for Polio Type 1, 2 and 3 ≥ the Cut-off

Seroprotection status was defined as Anti-polio type 1, Anti-polio type 2 and Anti-polio type 3 antibody titers ≥ 8.

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Geometric mean · Titers
Antibody Titers for Polio Type 1, 2 and 3 ≥ the Cut-off
TitersSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-Polio 1271.3 (132.9 to 554)189.5 (109.9 to 326.8)230.1 (166 to 319)
Anti-Polio 2341.7 (214 to 545.6)319 (172.5 to 589.8)194.4 (121.7 to 310.7)
Anti-Polio 3248.4 (67.9 to 908.7)344.7 (192.2 to 618.3)384.8 (245.3 to 603.6)
SecondaryNumber of Subjects With Vaccine Response to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)

Vaccine response to PT, FHA and PRN was defined as appearance of antibodies in subjects who are initially seronegative (S-), or at least maintenance of pre-vaccination antibody concentrations in those who are initially seropositive (S+). For the SYNFLORIX™ + INFANRIX™ HEXA GROUP I, no subjects presented initial seropositivity for PT and PRN antigens.

Time frame:
One month after the 3rd vaccine dose (Month 5)
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Response to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)
ParticipantsSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
Anti-PT, S-182745
Anti-PT, S+0812
Anti-FHA, S-152218
Anti-FHA, S+31741
Anti-PRN, S-173445
Anti-PRN, S+0412

Adverse events

Collected over Solicited local and general symptoms: during the 4-day post vaccination; Unsolicited AEs: during the 31-day post vaccination; SAEs: during the whole study period (Month 0 - Month 10, including the 5 months extended safety follow-up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Synflorix™ + Infanrix™ Hexa Group I1/50 (2%)17/50 (34%)42/50 (84%)
Synflorix™ + Infanrix™ Hexa Group II0/87 (0%)11/87 (12.6%)76/87 (87.4%)
Synflorix™ + Infanrix™ Hexa Group III0/149 (0%)19/149 (12.8%)136/149 (91.3%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
BronchiolitisInfections and infestations4/501/873/149
GastroenteritisInfections and infestations3/500/873/149
PneumoniaInfections and infestations2/500/871/149
Breath holdingPsychiatric disorders0/502/870/149
TachypnoeaRespiratory, thoracic and mediastinal disorders0/502/870/149
ThrombocythaemiaBlood and lymphatic system disorders1/500/870/149
Inguinal hernia, obstructiveGastrointestinal disorders1/500/870/149
VomitingGastrointestinal disorders1/500/870/149
IrritabilityGeneral disorders1/500/870/149
PyrexiaGeneral disorders1/500/872/149
Most frequent other events
Most frequent other events
EventSynflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group III
ErythemaSkin and subcutaneous tissue disorders24/5049/87102/149
IrritabilityPsychiatric disorders22/5053/87100/149
SwellingGeneral disorders20/5035/8798/149
PainGeneral disorders24/5041/8784/149
Decreased appetiteMetabolism and nutrition disorders19/5046/8751/149
PyrexiaGeneral disorders22/5045/8771/149
SomnolenceNervous system disorders20/5044/8765/149
Upper respiratory tract infectionInfections and infestations1/509/8710/149
Injection site noduleGeneral disorders0/504/8710/149

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Synflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group IIITotal
Mean11.0 ± 3.29.5 ± 1.459.3 ± 1.459.66 ± 1.97
Sex: Female, Male
Sex: Female, Male(Participants)Synflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group IIITotal
Female194062121
Male314787165
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Synflorix™ + Infanrix™ Hexa Group ISynflorix™ + Infanrix™ Hexa Group IISynflorix™ + Infanrix™ Hexa Group IIITotal
Race/Etnicity — White - Caucasian/ European heritage3677140253
Race/Etnicity — African heritage/ African american2147
Race/Etnicity — American Indian or Alaskan native46212
Race/Etnicity — Asian - south east Asian heritage0101
Race/Etnicity — White - Arabic/ north African heritage1023
Race/Etnicity — Other (unspecified)72110
08

Study locations

8 sites
  • GSK Investigational Site
    Athens, 115 27, Greece
  • GSK Investigational Site
    Athens, 11527, Greece
  • GSK Investigational Site
    Ioannina, 452 21, Greece
  • GSK Investigational Site
    Rio/Patras, 26500, Greece
  • GSK Investigational Site
    Thessaloniki, 54636, Greece
  • GSK Investigational Site
    Burgos, 09005, Spain
  • GSK Investigational Site
    Madrid, 28047, Spain
  • GSK Investigational Site
    Móstoles/Madrid, 28935, Spain
09

References and documents

Publications

  • Omenaca F, Merino JM, Tejedor JC, Constantopoulos A, Papaevangelou V, Kafetzis D, Tsirka A, Athanassiadou F, Anagnostakou M, Francois N, Borys D, Schuerman L. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics. 2011 Aug;128(2):e290-8. doi: 10.1542/peds.2010-1184. Epub 2011 Jul 4. PubMed 21727108 ↗
  • Omeneca F et al. Vaccination of pre-term infants with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHID-CV). Abstract presented at the 27th annual ESPID meeting, Brussels, Belgium, 9-13 June 2009.
  • Omeneca F et al. Immunogenicity and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) following primary and booster vaccination in preterm-born children. Abstract presented at Excellence In Paediatrics. Florence, Italy, 3-6 December 2009.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2006 to primary completion in Jul 2007, 9 months.

Results were first posted in Dec 2018, 11 years 5 months after primary completion. A results delay was requested in May 2009.

Of 28 industry-sponsored phase 3 interventional studies under Streptococcal Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 13. This study's 9 months is close to that.

Counting every sponsor, half of 29 studies reached it within 10 months; a quarter within 8 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2006
First posted
Oct 23, 2006
StartActual
Oct 1, 2006
Primary completionActual
Jul 2, 2007
CompletionActual
May 2, 2008
Results delay requested
May 20, 2009
Results first posted
Dec 17, 2018
Last update
Dec 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00390910
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 23, 2006
Start date
Oct 1, 2006
Primary completion
Jul 2, 2007
Completion
May 2, 2008
Results posted
Dec 17, 2018
Last update
Dec 17, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion